Japan first to approve Novartis' blockbuster hopeful Cosentyx; Bayer, Hospira win FDA nods;

> Japan has approved Novartis' ($NVS) Cosentyx as a treatment for psoriasis and psoriatic arthritis. Release

> The FDA has green-lighted Bayer's Gadavist injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age. Release

> The FDA has given Hospira ($HSP) a thumbs-up for its analgesic Dyloject injection, a treatment for pain management. Release

> Angelini will market Ariad's ($ARIA) Iclusig in Eastern Europe. Report

> Pfizer ($PFE) has granted Georgia State $850,000 to partner with Chinese health officials to expand tobacco control efforts in China's major cities. More

> The Asia-Pacific market for Type 2 diabetes treatments will hit $10.5 billion by 2020, GBI Research predicts. Release

And Finally... The Gates Foundation is using art to encourage vaccination. Story (sub. req.)

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.